PubMed · 9130980
The source did not provide an abstract. Follow the original record for more information.
Explore connections, maps & timelines
R Colebunders, G Beelaert, R Wellens. 1997-04-26. HIV testing in developing countries.. https://doi.org/10.1016/s0140-6736(05)62460-9
Cite the original work for its findings. Save a collection to share your selection of sources.
KEEP EXPLORING
A new immunochromatographic rapid test, Determine HIV-1/2, for the detection of antibodies to human immunodeficiency virus type 1 (HIV-1) and HIV-2 in human whole blood, serum, and plasma was evaluated. Determine HIV-1/2 is a sandwich immunoassay and uses a nitrocellulose strip with a capture site for the patient's results and a procedural control site to confirm the validity of the assay. The results can be read visually, and a positive result is indicated by the formation of a red line within 15 min after sample application. The test showed 100% sensitivity for HIV-1 with 102 whole-blood, 152 serum, and 144 plasma samples obtained from Ramathibodi Hospital, Bangkok, Thailand. The sensitivity of the test for HIV-2 was 100% with 100 serum or plasma samples obtained from Ivory Coast. The sensitivity of the test with 4 anti-HIV-1 seroconversion panels from Boston Biomedica Inc. was equivalent to or better than those of another agglutination assay with serum or plasma and the enzyme immunoassay licensed by the U.S. Food and Drug Administration. The specificity was 100% with 367 sets of whole-blood, serum, and plasma samples from Ramathibodi Hospital. This method had an analytical sensitivity for the detection of HIV-1 equivalent to or better than that of another agglutination assay with serum or plasma. This test had an analytical sensitivity for the detection of HIV-1 better than that of another immunochromatographic test with whole blood. This evaluation demonstrated the excellent performance of this immunochromatographic test with EDTA-anticoagulated whole-blood, serum, and plasma samples. We conclude that this test is suitable for use in emerging countries and is an excellent alternative to HIV antibody testing at remote sites, as well as in traditional laboratories.
Extending acquired immunodeficiency syndrome (AIDS) case surveillance systems to include confidential (name-based) reporting of human immunodeficiency virus (HIV) infections provides data representing recent HIV transmission patterns. These data may improve the ability of public health agencies to plan and evaluate HIV prevention and treatment services. Thirty-two states conduct name-based HIV infection case surveillance as an extension of AIDS case surveillance, and such surveillance is being considered in other states. Some community representatives and public health officials, however, are concerned that HIV infection surveillance may deter some at-risk persons from seeking HIV testing. This report describes the results of a survey conducted to assess deterrents to HIV testing in populations at risk for HIV infection during 1995 and 1996. The findings indicate that in these populations knowledge of state HIV reporting policies was low, and fear of a positive HIV test result and a lack of perceived risk for HIV infection were the most common deterrents to testing in all risk groups. However, untested men who have sex with men (MSM) who resided in states with name-based reporting cited concerns about reporting as a reason they had not tested more often than untested MSM in states without name-based reporting.
OBJECTIVE: To evaluate acceptability of voluntary HIV counselling and testing (VCT) by pregnant women in the context of clinical trials assessing interventions to reduce mother-to-child transmission (MCT) of HIV in developing countries. METHODS: During September-October 1997, 13 studies located in West (Abidjan, Bobo Dioulasso), East (Nairobi, Mombasa, Dar Es Salaam, Blantyre, Lusaka, Harare) and South Africa (Soweto, Durban), and Thailand (Bangkok) were included in a cross-sectional mailing survey about the acceptability of VCT in antenatal clinics. Acceptance rate, return rate, overall acceptability of VCT (acceptance of both pre- and post-VCT sessions) were obtained using a standardized questionnaire. RESULTS: The median overall acceptability of VCT was 69% (range, 33-95%). Overall acceptability of VCT most frequently depended on return rates because acceptance rates were generally high. Where several studies were conducted in parallel in the same city or the same country, overall acceptability rates of HIV testing were generally comparable even if the intervention programmes differed. Overall acceptability rates of VCT were high in antenatal clinics where a particular effort in implementing VCT programmes had been made. CONCLUSIONS: This international survey shows that despite many obstacles, VCT is feasible and acceptable for pregnant women aiming to reduce their risk of transmitting HIV to their children.